IDEXX LABORATORIES INC /DE
IDXXPharma & biotechidexx.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 2, 2026
Next reportFebruary 1, 2027after close · forecast 3.466 $/share
Revenue
$1.21B
▲ +9.9% vs prior year YoY
Net income
$317.14M
▲ +15.5% vs prior year YoY
EPS
4.01$
▲ +17.9% vs prior year YoY
Net margin
26.1%
▲ +1.3 pp vs prior year YoY
Revenue▲ +9.9%
Margins (% of revenue)GrossOperatingNet
Net income▲ +15.5%
EPS▲ +17.9%
Financial statements
View 10-Q filed November 2, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $954.29M | $998.43M | $1.11B | $1.11B | $1.09B | $1.14B | $1.22B | $1.21B | ▲ +9.9% |
| Gross profit | $570.66M | $623.38M | $694.73M | $683.35M | $658.11M | $722.74M | $779.09M | $764.30M | ▲ +11.8% |
| Operating income | $261.69M | $316.53M | $373.05M | $354.85M | $315.61M | $362.59M | $425.57M | $402.35M | ▲ +13.4% |
| Net income | $216.15M | $242.68M | $293.99M | $274.61M | $248.19M | $278.45M | $338.41M | $317.14M | ▲ +15.5% |
| R&D | $57.73M | $59.06M | $61.90M | $63.41M | $66.83M | $65.79M | $65.43M | $68.82M | ▲ +8.5% |
| EPS (diluted) | — | 2.96 $ | 3.63 $ | 3.40 $ | — | 3.47 $ | 4.27 $ | 4.01 $ | ▲ +17.9% |
| Margins (% of revenue) | |||||||||
| Gross | 59.8 % | 62.4 % | 62.6 % | 61.8 % | 60.3 % | 63.4 % | 64.0 % | 62.9 % | ▲ +1.1 pt |
| Operating | 27.4 % | 31.7 % | 33.6 % | 32.1 % | 28.9 % | 31.8 % | 35.0 % | 33.1 % | ▲ +1.0 pt |
| Net | 22.7 % | 24.3 % | 26.5 % | 24.8 % | 22.8 % | 24.4 % | 27.8 % | 26.1 % | ▲ +1.3 pt |
| Balance sheet | |||||||||
| Assets | $3.29B | $3.21B | $3.33B | $3.39B | $3.35B | $3.39B | $3.44B | $3.71B | ▲ +9.5% |
| Liabilities | $1.70B | $1.77B | $1.87B | $1.83B | $1.75B | $1.83B | $1.83B | $1.84B | ▲ +0.7% |
| Equity | $1.60B | $1.45B | $1.46B | $1.56B | $1.61B | $1.56B | $1.61B | $1.87B | ▲ +19.7% |
| Cash | $288.27M | $163.97M | $164.59M | $208.17M | $180.07M | $200.53M | $196.93M | $197.54M | ▼ -5.1% |
| Capital | |||||||||
| Shares outstanding | 81.33M | 80.42M | 80.00M | 79.85M | 79.62M | 78.88M | 78.78M | 78.79M | ▼ -1.3% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.